Efficacy and Safety of 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy for Non-Hodgkin's Lymphoma

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and Safety of <sup>90</sup>Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy for Non-Hodgkin's Lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences